IL-4 is an anti-inflammatory cytokine, and we detected a significant increase in serum IL-4 in NSCLC patients, which may contribute to the survival, growth, and metastasis of tumor cells. This evidence concerns the gene IL4 and non-small cell lung carcinoma.